New hope for Tough-to-Treat lymphoma: mosunetuzumab under review
NCT ID NCT07278921
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 21 times
Summary
This study looks at how well the drug mosunetuzumab works for people with follicular lymphoma that has come back or not responded to at least two prior treatments. Researchers will review medical records from 25 patients who received the drug through a compassionate use program. The goal is to measure tumor shrinkage and how long patients stay cancer-free, while also tracking side effects like infusion reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Ospedale San Raffaele
RECRUITINGMilan, 20132, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.